Summarizing the above, we conducted a study of triple-negative breast cancer samples (n = 161), confirmed by histological and immunohistochemical examination (ER−/0; PR−/0; HER2/neu −/0), with antibodies to NIS and subsequent comparison with the gravidity status of patients. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.